NCT07256184Completed
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
Evaluation of Clinical, Pathologic, and Molecular Determinants of Prognosis and Treatment Response in Patients With Metastatic Malignant Melanoma: A Multicenter Retrospective Study
Source: ClinicalTrials.gov · Last updated 15 Dec 2025
Brief summary (registry, in English)
This multicenter, retrospective observational study aims to identify clinical, pathological, and molecular factors associated with prognosis and treatment response in patients with metastatic malignant melanoma. Medical records of adult patients diagnosed and treated between November 2022 and December 2024 at participating oncology centers in Türkiye were reviewed. Data collected include demographic features, disease characteristics, histopathologic findings, treatment modalities (immune checkpoint inhibitors, targeted therapy, or chemotherapy), and dermatologic adverse events. These variables will be analyzed in relation to survival outcomes to provide real-world evidence supporting personalized management strategies in metastatic melanoma.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 232 (actual)
- First submitted
- 20 Nov 2025
- Start date
- 15 Nov 2022
- Primary completion date
- 15 Dec 2024
- Lead sponsor
- Ankara Etlik City Hospital
- Diseases
- Melanoma
- NCT number
- NCT07256184
What you commit to
- Study type: Observational
- Participants enrolled: 232
- From 15 Nov 2022 to the primary completion date, 15 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Another primary malignancy (except allowed types)
Other
- Incomplete clinical or pathological data
- Uncertain or revised diagnosis
- Metastasis developing outside the inclusion window
- Lost to follow-up before first response assessment
Who the study is looking for
- Age ≥18 years
- Histologically or cytologically confirmed metastatic malignant melanoma
- Received ≥1 line of systemic therapy
- Complete baseline and follow-up data
- At least one measurable lesion or clinical response assessment
- Managed between November 2022 - December 2024 at participating centers
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ankara Etlik City Hospital Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
| Gazi University Medical Oncology Department Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.